AC

Atul Chandrakant Shah

Director Director DIN 05104150
DIN 05104150 First appointment Oct 2011 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Oct 2011
Shareholding value •••• Premium profile

About Atul Chandrakant Shah

Data last updated:

Atul Chandrakant Shah was a Director at Nishchem International Private Limited (2011–2022) and Designated Partner at Remedynia Curantis Llp (2017–2020). The companies operate in Pharma and Healthcare.

DIN 05104150
Primary Designation Director
Industry Pharma
First Appointment 21 Oct 2011

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director21 Oct 20112011₹250 Cr (FY 2025)Active
Designated Partner22 Aug 20172017Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Nishchem International Private Limited
Remedynia Curantis Llp
Premium access

Shareholding and investment profile for Atul Chandrakant Shah

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Atul Chandrakant Shah

Atul Chandrakant Shah was first appointed on 21 Oct 2011 as Director at Nishchem International Private Limited. The most recent appointment on record is 22 Aug 2017 at Remedynia Curantis Llp.

Atul Chandrakant Shah held 2 earlier board appointments: Nishchem International Private Limited (Director, 21 Oct 2011 to 21 May 2022); Remedynia Curantis Llp (Designated Partner, 22 Aug 2017 to 17 Jan 2020).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available